Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FBI Unveils Science of Anthrax Investigation

By Drug Discovery Trends Editor | August 25, 2008

 

bacillus anthracis spores 
click to enlarge 
 
bacillus anthracis spores as viewed in SEM (left) and TEM (right). (Photo courtesy of Sandia National Laboratories)

Most people did not know that the work in Ray Goehner’s materials characterization department at Sandia National Laboratories was contributing important information to the FBI’s investigation of letters containing bacillus anthracis, the spores that cause the disease anthrax. The spores were mailed in the fall of 2001 to several news media offices and to two U.S. senators. Five people were killed.

Sandia’s work demonstrated to the FBI that the form of bacillus anthracis contained in those letters was not a weaponized form, a form of the bacteria prepared to disperse more readily. The possibility of a weaponized form was of great concern to investigators, says Joseph Michael, the principal investigator for the project. This information was crucial in ruling out state-sponsored terrorism.

In fall of 2001, the FBI considered how to best investigate the anthrax letters. The agency convened two blue ribbon exploratory panels, and Sandia’s name came up during both panels for its expertise in electron and ion microscopies and microanalysis over the range of length scales from millimeters down to nanometers. The first spore material from the letters arrived at Sandia in February of 2002.

Sandia faced some uncertainty in working on this type of investigation. Researchers signed nondisclosure agreements and agreed to make themselves available to government agencies on short notice when called to give information.

Release date: August 21, 2008
Source: Sandia National Laboratories


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50